Semaglutide: A New Hope for Alcohol Use Disorder?
Episode Overview
Semaglutide may reduce the incidence and recurrence of alcohol use disorder. THC products that look like candy pose a significant risk to children. Excessive opioid prescriptions post-surgery remain a concern. GLP-1 receptor agonists could be a game-changer in addiction treatment. Patient experiences provide valuable insights into medication efficacy.
This medication is not going to come and just like slap the drink out of your hand.
If you're curious about the latest research on treating alcohol use disorder, this episode of the Addiction Medicine Journal Club is a must-listen. Dr. John Kean and Dr. Sonia Del Tredici dive into the potential of semaglutide, a GLP-1 receptor agonist, to help those struggling with alcohol addiction. They break down a comprehensive study published in Nature Communication that explores how semaglutide might reduce the incidence and recurrence of alcohol use disorder.
Alongside this main topic, the episode also touches on the dangers of THC products disguised as candy and the ongoing issue of excessive opioid prescriptions post-surgery. The hosts share personal anecdotes and clinical experiences, making complex medical research accessible and engaging. Whether you're a healthcare professional or someone looking for new insights into addiction treatment, this episode offers valuable information with a touch of humour.
Tune in to learn about the promising intersection of weight loss medications and addiction therapy, and how these findings could impact future treatment approaches.